BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 25371178)

  • 41.
    Aptullahoglu E; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511096
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
    Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
    Sciumè M; Vincenti D; Reda G; Orofino N; Cassin R; Giannarelli D; Gaidano G; Rossi D; Cortelezzi A
    Am J Hematol; 2015 Nov; 90(11):970-4. PubMed ID: 26201283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Analysis of SF3B1 mutations in monoclonal B-cell lymphocytosis.
    Greco M; Capello D; Bruscaggin A; Spina V; Rasi S; Monti S; Ciardullo C; Cresta S; Fangazio M; Gaidano G; Foà R; Rossi D
    Hematol Oncol; 2013 Mar; 31(1):54-5. PubMed ID: 22461140
    [No Abstract]   [Full Text] [Related]  

  • 47. Subclonal evolution involving SF3B1 mutations in chronic lymphocytic leukemia.
    Schwaederlé M; Ghia E; Rassenti LZ; Obara M; Dell'Aquila ML; Fecteau JF; Kipps TJ
    Leukemia; 2013 Apr; 27(5):1214-7. PubMed ID: 23337928
    [No Abstract]   [Full Text] [Related]  

  • 48. IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.
    Rizzo D; Chauzeix J; Trimoreau F; Woillard JB; Genevieve F; Bouvier A; Labrousse J; Poli C; Guerin E; Dmytruk N; Remenieras L; Feuillard J; Gachard N
    Leukemia; 2015 Feb; 29(2):337-45. PubMed ID: 24943833
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting treatment outcomes in CLL.
    Wiestner A
    Blood; 2014 May; 123(21):3212-4. PubMed ID: 24855188
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biallelic ATM alterations detected at diagnosis identify a subset of treatment-naïve chronic lymphocytic leukemia patients with reduced overall survival similar to patients with p53 deletion.
    Lozano-Santos C; García-Vela JA; Pérez-Sanz N; Nova-Gurumeta S; Fernandez-Cuevas B; Gomez-Lozano N; Sánchez-Beato M; Sanchez-Godoy P; Bueno JL; Garcia-Marco JA
    Leuk Lymphoma; 2017 Apr; 58(4):859-865. PubMed ID: 27499002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.
    Athanasakis E; Melloni E; Rigolin GM; Agnoletto C; Voltan R; Vozzi D; Piscianz E; Segat L; Dal Monego S; Cuneo A; Secchiero P; Zauli G
    Oncotarget; 2014 Dec; 5(24):12635-45. PubMed ID: 25587027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. SF3B1 mutation and ATM deletion codrive leukemogenesis via centromeric R-loop dysregulation.
    Cusan M; Shen H; Zhang B; Liao A; Yang L; Jin M; Fernandez M; Iyer P; Wu Y; Hart K; Gutierrez C; Nik S; Pruett-Miller SM; Stark J; Obeng EA; Bowman TV; Wu CJ; Lin RJ; Wang L
    J Clin Invest; 2023 Sep; 133(17):. PubMed ID: 37463047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Present status and perspectives in functional analysis of p53 in chronic lymphocytic leukemia.
    de Viron E; Michaux L; Put N; Bontemps F; Van Den Neste E
    Leuk Lymphoma; 2012 Aug; 53(8):1445-51. PubMed ID: 22280536
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1.
    Tausch E; Beck P; Schlenk RF; Jebaraj BJ; Dolnik A; Yosifov DY; Hillmen P; Offner F; Janssens A; Babu GK; Grosicki S; Mayer J; Panagiotidis P; McKeown A; Gupta IV; Skorupa A; Pallaud C; Bullinger L; Mertens D; Döhner H; Stilgenbauer S
    Haematologica; 2020 Oct; 105(10):2440-2447. PubMed ID: 33054084
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
    Wang L; Brooks AN; Fan J; Wan Y; Gambe R; Li S; Hergert S; Yin S; Freeman SS; Levin JZ; Fan L; Seiler M; Buonamici S; Smith PG; Chau KF; Cibulskis CL; Zhang W; Rassenti LZ; Ghia EM; Kipps TJ; Fernandes S; Bloch DB; Kotliar D; Landau DA; Shukla SA; Aster JC; Reed R; DeLuca DS; Brown JR; Neuberg D; Getz G; Livak KJ; Meyerson MM; Kharchenko PV; Wu CJ
    Cancer Cell; 2016 Nov; 30(5):750-763. PubMed ID: 27818134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.
    Maura F; Cutrona G; Mosca L; Matis S; Lionetti M; Fabris S; Agnelli L; Colombo M; Massucco C; Ferracin M; Zagatti B; Reverberi D; Gentile M; Recchia AG; Bossio S; Rossi D; Gaidano G; Molica S; Cortelezzi A; Di Raimondo F; Negrini M; Tassone P; Morabito F; Ferrarini M; Neri A
    Leuk Lymphoma; 2015; 56(11):3150-8. PubMed ID: 25860243
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Chronic lymphocytic leukemia: diagnosis and gene mutations].
    Aoki S
    Rinsho Ketsueki; 2014 Oct; 55(10):1981-8. PubMed ID: 25297763
    [No Abstract]   [Full Text] [Related]  

  • 59. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
    Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
    Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic characterization of SF3B1 mutations in single chronic lymphocytic leukemia cells.
    Wu X; Tschumper RC; Jelinek DF
    Leukemia; 2013 Nov; 27(11):2264-7. PubMed ID: 23685408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.